Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.66 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.66 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA7 | P43166 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL129801 | 0.88 | CYP4F2 (0.71) | CYP4F2CYP4A11MEP1BNPC1RAB9A | |
| SCHEMBL321524 | 0.87 | CYP4F2 (0.71) | CYP4F2CYP4A11MEP1BNPC1RAB9A | |
| SCHEMBL6527211 | 0.87 | LMNA (0.60) | CYP4F2CYP4A11MEP1BRAB9AALDH1A1 | |
| SCHEMBL3118174 | 0.86 | TDP1 (0.50) | CYP4F2CYP4A11MEP1BNPC1RAB9A | |
| SCHEMBL2089661 | 0.85 | CYP4F2 (0.68) | CYP4F2CYP4A11MEP1BNPC1RAB9A | |
| SCHEMBL128387 | 0.85 | CYP4F2 (0.72) | CYP4F2CYP4A11MEP1BNPC1RAB9A | |
| SCHEMBL27537771 | 0.84 | TSHR (0.54) | CYP4F2CYP4A11NPC1RAB9AALDH1A1 | |
| SCHEMBL110276 | 0.84 | CYP4F2 (0.65) | CYP4F2CYP4A11NPC1RAB9AALDH1A1 | |
| SCHEMBL318600 | 0.83 | TDP1 (0.71) | NPC1RAB9AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL129800 | 0.83 | CYP4F2 (0.66) | CYP4F2CYP4A11MEP1BNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119684287-A | 4- (3- (Piperidin-4-yl) -1H-pyrazol-5-yl) -1H-pyrrole [2,3-b ] pyridine derivative, and preparation method and application thereof | 烟台新药创制山东省实验室 | 2025-03-25 | — | — | CN | disclosed |
| US-20230011131-A1 | NOVEL COMPOUND FOR INHIBITING HISTONE ACETYLTRANSFERASE P300 AND ANTI-FIBROSIS COMPOSITION COMPRISING SAME | REFURE LIFE SCIENCE, INC. (KR) | 2023-01-12 | — | — | US | disclosed |
| US-20220194911-A1 | NOVEL COMPOUND FOR INHIBITING HISTONE ACETYLTRANSFERASE P300 AND ANTIFIBROTIC COMPOSITION COMPRISING SAME | REFURE LIFE SCIENCE, INC. (KR) | 2022-06-23 | — | — | US | disclosed |
| EP-4011862-A1 | NOVEL COMPOUND FOR INHIBITING HISTONE ACETYLTRANSFERASE P300 AND ANTI-FIBROSIS COMPOSITION COMPRISING SAME | Refure Life Science Inc. (KR) | 2022-06-15 | — | — | EP | disclosed |
| CN-110452168-B | N-phenyl-N-quinoline carboxylic acid compound and preparation method and pharmaceutical application thereof | 中国医学科学院药物研究所 | 2022-03-15 | — | — | CN | disclosed |
| WO-2021025448-A1 | NOVEL COMPOUND FOR INHIBITING HISTONE ACETYLTRANSFERASE P300 AND ANTIFIBROTIC COMPOSITION COMPRISING SAME | 리퓨어생명과학 주식회사 | 2021-02-11 | — | — | WO | disclosed |
| WO-2021025447-A1 | NOVEL COMPOUND FOR INHIBITING HISTONE ACETYLTRANSFERASE P300 AND ANTI-FIBROSIS COMPOSITION COMPRISING SAME | 리퓨어생명과학 주식회사 | 2021-02-11 | — | — | WO | disclosed |
| US-10807959-B2 | WDR5-MLL1 inhibitors and modulators | VANDERBILT UNIVERSITY (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200055824-A1 | WDR5-MLL1 INHIBITORS AND MODULATORS | VANDERBILT UNIVERSITY | 2020-02-20 | — | — | US | disclosed |
| CN-110452168-A | N- phenyl-N- quinoline carboxylic acid compound and its preparation method and medicinal usage | INST MATERIA MEDICA CAMS | 2019-11-15 | — | — | CN | disclosed |
| US-5587504-A | Sulfonyloxy-biphenylcarboxylic ester derivatives which are intermediates | EISAI CO., LTD. (JP) | 1996-12-24 | — | — | US | disclosed |
| US-5583229-A | Process for the preparation of imidazopyridine derivatives | EISAI CO., LTD. (JP) | 1996-12-10 | — | — | US | disclosed |
| US-5563158-A | CARDIOVASCULAR DISORDERS | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-10-08 | — | — | US | disclosed |
| US-5559236-A | Intermediates for substituted biphenylmethylmidazopyridine angiotensin II antagonists | EISAI CO., LTD. (JP) | 1996-09-24 | — | — | US | disclosed |
| US-5557002-A | Process for the preparation of biphenyl containing intermediates useful in making angiotensin II receptor antagonists | EISAI CO., LTD. (JP) | 1996-09-17 | — | — | US | disclosed |
| US-5554757-A | Process for the preparation of imidazopyridine derivatives, and intermediates therefore | EISAI CO., LTD. (JP) | 1996-09-10 | — | — | US | disclosed |
| EP-0315399-B1 | Quinoline derivatives, their use in the treatment of hypersensitive ailments and a pharmaceutical composition containing the same | RHONE POULENC RORER INT (US) | 1996-01-10 | — | — | EP | disclosed |
| EP-0627433-A1 | PROCESS FOR PRODUCING IMIDAZOPYRIDINE DERIVATIVE AND INTERMEDIATE | Eisai Co., Ltd. (JP) | 1994-12-07 | — | — | EP | disclosed |
| US-5059610-A | QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1991-10-22 | — | — | US | disclosed |
| US-4920132-A | Quinoline derivatives and use thereof as antagonists of leukotriene D4 | RORER PHARMACEUTICAL CORP. (US) | 1990-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230011131-A1 | NOVEL COMPOUND FOR INHIBITING HISTONE ACETYLTRANSFERASE P300 AND ANTI-FIBROSIS COMPOSITION COMPRISING SAME | EP300, HDAC1, KAT2A | CYP4F2 4713/4885CYP4A11 4465/4885MEP1B 1308/4885 |
| US-20220194911-A1 | NOVEL COMPOUND FOR INHIBITING HISTONE ACETYLTRANSFERASE P300 AND ANTIFIBROTIC COMPOSITION COMPRISING SAME | EP300, HDAC1, HDAC11 | CYP4F2 4659/4885CYP4A11 4413/4885MEP1B 1028/4885 |
| US-10807959-B2 | WDR5-MLL1 inhibitors and modulators | WDR5, WDR1, WDR3 | CYP4F2 4403/4885CYP4A11 4429/4885MEP1B 1708/4885 |
| US-20200055824-A1 | WDR5-MLL1 INHIBITORS AND MODULATORS | WDR5, WDR1, WDR3 | CYP4F2 4403/4885CYP4A11 4429/4885MEP1B 1708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.